3-hydroxyquinazoline derivatives, analogues of erastin, induce ferroptosis in colorectal cancer cells

V. N. Osipov; Осипов В. Н.; A. A. Vartanyan; Вартанян А. А.; D. A. Khochenkov; Хоченков Д. А.; D. V. Gusev; Гусев Д. В.; O. V. Fateenkova; Фатеенкова О. В.; D. S. Khachatryan; Хачатрян Д. С.; L. M. Borisova; Борисова Л. М.

doi:10.31857/S0132342324050033

3-hydroxyquinazoline derivatives, analogues of erastin, induce ferroptosis in colorectal cancer cells

Authors: Osipov V.N.¹, Vartanyan A.A.¹, Khochenkov D.A.¹, Gusev D.V.¹, Fateenkova O.V.², Khachatryan D.S.³, Borisova L.M.¹
Affiliations:
1. N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
2. I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
3. National Research Center “Kurchatov Institute”
Issue: Vol 50, No 5 (2024)
Pages: 601-611
Section: Articles
URL: https://rjmseer.com/0132-3423/article/view/670789
DOI: https://doi.org/10.31857/S0132342324050033
EDN: https://elibrary.ru/LRZRMB
ID: 670789

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract

In recent years, significant progress has been achieved in the treatment of patients with colon cancer, but in most cases treatment is accompanied by the development of drug resistance. Recently discovered iron-dependent cell death, ferroptosis, makes it a promissing therapeutic target to reduce the recurrence rates. In this study we have examined the effect of 3-hydoxyquinazoline derivatives on ferroptosis induction in two colon cancer cells HCT-116 and DLD-1. The ferroptotic cell death was identified by the level of lipid peroxidation. The level of lipid peroxidation in HCT-116 cells induced by some compounds approached the activity of the reference drug erastin. This scenario changed significantly when the ferroptosis induction was studied in DLD-1 cells. Two 3-hydroxyquinazoline derivatives induced levels of lipid peroxidation in DLD-1 cells that exceeded those of erastin. The preliminary results obtained suggest that three new compounds can be considered as an antitumor agent for the treatment of colon cancer, and also indicate the prospects of further searching for ferroptosis inducers among 3-hydroxyquinazoline derivatives.

Keywords

quinazoline’ derivatives synthesis, colorectal cancer, cytotoxic activity, ferroptosis induction

Full Text

About the authors

V. N. Osipov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Author for correspondence.
Email: ovn65@yandex.ru
Russian Federation, Kashirskoe shosse 24, Moscow, 115478

A. A. Vartanyan

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Russian Federation, Kashirskoe shosse 24, Moscow, 115478

D. A. Khochenkov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Russian Federation, Kashirskoe shosse 24, Moscow, 115478

D. V. Gusev

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Russian Federation, Kashirskoe shosse 24, Moscow, 115478

O. V. Fateenkova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Email: ovn65@yandex.ru
Russian Federation, ul. Trubetskaya 8/2, Moscow, 119991

D. S. Khachatryan

National Research Center “Kurchatov Institute”

Email: ovn65@yandex.ru
Russian Federation, pl. Akad. Kurchatova 1, Moscow, 123182

L. M. Borisova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Russian Federation, Kashirskoe shosse 24, Moscow, 115478

References

Fabregas J.C., Ramnaraign B., George T.J. // Clin. Colorectal Cancer. 2022. V. 21. P. 198–203. https://doi.org/10.1016/j.clcc.2022.05.006
Grazzini G., Danti G., Chiti G., Giannessi C., Pradella S., Miele V. // Diagnostics (Basel). 2023. V. 13. P. 2104–2115. https://doi.org/10.3390/diagnostics13122104
Afrăsânie V.A., Marinca M.V., Alexa-Stratulat T., Gafton B., Păduraru M., Adavidoaiei A.M., Miron L., Rusu C. // Radiol. Oncol. 2019. V. 53. P. 265–274. https://doi.org/10.2478/raon-2019-0033
Kozovska Z., Gabrisova V., Kucerova L. // Biomed. Pharmacother. 2014. V. 68. P. 911–916. https://doi.org/10.1016/j.biopha.2014.10.019
Van der Jeught K., Xu H.C., Li Y.J., Lu X.B., Ji G. // World J. Gastroenterol. 2018. V. 24. P. 3834–3848. https://doi.org/10.3748/wjg.v24.i34.3834
Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., Morrison B., 3rd, Stockwell B.R. // Cell. 2012. V. 149. P. 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
Negri F., Bottarelli L., de’Angelis G.L., Gnetti L. // Int. J Mol. Sci. 2022. V. 23. P. 4120–4128. https://doi.org/10.3390/ijms23084120
Zhang C., Liu X., Jin S., Chen Y., Guo R. // Mol. Cancer. 2022. V. 21. P. 47–59. https://doi.org/10.1186/s12943-022-01530-y
Prutki M., Poljak-Blazi M., Jakopovic M., Tomas D., Stipancic I., Zarkovic N. // Cancer Lett. 2006. V. 238. P. 188–96. https://doi.org/10.1016/j.canlet.2005.07.001
Demir H., Beypinar I., Urvay S., Davarci S.E., Baykara M. // Eur. Rev. Med. Pharmacol. Sci. 2021. V. 25. P. 6473–6479. https://doi.org/10.26355/eurrev_202111_27091
Xu T., Ding W., Ji X., Ao X., Liu Y., Yu W., Wang J. // J. Cell Mol Med. 2019. V. 23. P. 4900–4912. https://doi.org/10.1111/jcmm.14511
Galluzzi L., Vitale I., Warren S., Adjemian S., Agostinis P., Martinez A.B., Chan T.A., Coukos G., Demaria S., Deutsch E., Draganov D., Edelson R.L., Formenti S.C., Fucikova J., Gabriele L., Gaipl U.S., Gameiro S.R., Garg A.D., Golden E., Han J., Harrington K.J., Hemminki A., Hodge J.W., Hossain D.M.S., Illidge T., Karin M., Kaufman H.L., Kepp O., Kroemer G., Lasarte J.J., Loi S., Lotze M.T., Manic G., Merghoub T., Melcher A.A., Mossman K.L., Prosper F., Rekdal Ø., Rescigno M., Riganti C., Sistigu A., Smyth M.J., Spisek R., Stagg J., Strauss B.E., Tang D., Tatsuno K., van Gool S.W., Vandenabeele P., Yamazaki T., Zamarin D., Zitvogel L., Cesano A., Marincola F.M. // J. Immunother. Cancer. 2020. V. 8. P. e000337. https://doi.org/10.1136/jitc-2019-000337
Sprooten J., De Wijngaert P., Vanmeerbeerk I., Martin S., Vangheluwe P., Schlenner S., Krysko D.V., Parys J.B., Bultynck G., Vandenabeele P., Garg A.D. // Cells. 2020. V. 9. P. 1823. https://doi.org/10.3390/cells9081823
Wiernicki B., Maschalidi S., Pinney J., Adjemian S., Vanden Berghe T., Ravichandran K.S., Vandenabeele P. // Nat. Commun. 2022. V. 13. P. 3676. https://doi.org/10.1038/s41467-022-31218-2
Борисова Л.М., Осипов В.Н., Гусев Д.В. Голубева И.С., Киселева М.П., Вартанян А.А. // Рос. биотерапевтич. журнал. 2021. Т. 20. С. 67–73. https://doi.org/10.17650/1726-9784-2021-20-1-67-73
Борисова Л.М., Осипов В.Н., Голубева И.С., Киселева М.П., Хоченков Д.А., Вартанян А.А. // Усп. мол. онкологии. 2022. Т. 9. С. 48–56. https://doi.org/10.17650/2313-805X-2022-9-1-48-56
Wang Y., Wu X., Ren Z., Li Y., Zou W., Chen J., Wang H. // Drug Resist. Updat. 2023. V. 66. P. 100916. https://doi.org/10.1016/j.drup.2022.100916
Вартанян А.А., Осипов В.Н., Хоченков Д.А., Гусев Д.В., Борисова Л.М. // Патент RU 2722308 С1, опубл. 28.05.2020.
Trainer D.L., Kline T., McCabe F.L., Faucette L.F., Feild J., Chaikin M., Anzano M., Rieman D., Hoffstein S., Li D.J., Gennaro D., Buscarino C., Lynch M., Poste G., Greig R. // Int. J. Cancer. 1988. V. 41. P. 287–296. https://doi.org/10.1002/ijc.2910410221
Chen S.K., Ma W.Q., Yan Z.B., Zhang F.M., Wang S.H., Nu Y.Q., Zhang X.M., Tian J.M. // J. Am. Chem. Soc. 2018. V. 140. P. 10099–10103. https://doi.org/10.3389/fphar.2017.00992
Martinez A.M., Kim A., Yang W.S. // Methods Mol. Biol. 2020. V. 2108. P. 125–130. https://doi.org/10.1007/978-1-0716-0247-8_11
Sakata S., Larson D.W. // Surg. Oncol. Clin. N. Am. 2022. V. 31. P. 255–264. https://doi.org/10.1016/j.soc.2021.11.006
Zhang C., Liu X., Jin S., Chen Y., Guo R. // Mol. Cancer. 2022. V. 21. P. 47–58. https://doi.org/10.1186/s12943-022-01530-y

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

2. Fig. 1. Effect of compound (VIIa) on the induction of ferroptosis in HCT-116 cells: (a) – control – cell growth with 5% DMSO; (b) – cell growth with 1/3 IC50 erastin; (c) – cell growth with 1/3 IC50 of compound (VIIa). Scale bar – 100 µm.

Download (151KB)

Indexing metadata

3. Fig. 2. Quantitative characteristics of the intensity of lipid peroxidation in HCT-116 and DLD-1 cells. K – fluorescence intensity induced by erastin, 1–7 – compounds (VIIa–g), respectively. Data are presented as mean ± standard deviation, p < 0.05.

Download (69KB)

Indexing metadata

4. Scheme 1. Synthesis of 3-hydroxyquinozaline derivatives. Reagents and conditions: i – CH2Cl2/H2O, thiophosgene; ii – AcONa, H2O; iii – NaOH, NH2OH . HCl, H2O; iv – NH2NH2 . H2O, ethanol; v – acetylacetone, ethanol; vi – benzyl chloroacetate, K2CO3, DMF.